Chlamydia-induced arthritis

Current Opinion in Rheumatology

Volumn 16, Issue 4, 2004, Pages 380-392

  Zeidler, Henning ^a   Kuipers, Jens ^a   Köhler, Lars ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chlamydia molecular diagnostics; Chlamydia host cell interaction; Chlamydia induced arthritis; HLA B27; Persistent infection

Indexed keywords

ANTIBIOTIC AGENT; ANTIRHEUMATIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; GLUCOCORTICOID; HLA B27 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN INHIBITOR; SALAZOSULFAPYRIDINE; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

BACTERIAL ARTHRITIS; BACTERIUM DETECTION; CELL INTERACTION; CHLAMYDIA; CHLAMYDIASIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; ENTHESITIS; EPIDEMIOLOGICAL DATA; GENE EXPRESSION; HOST CELL; HUMAN; IMMUNOPATHOGENESIS; INCIDENCE; MOLECULAR HYBRIDIZATION; PERSISTENT INFECTION; PHYSIOTHERAPY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; REACTIVE ARTHRITIS; REVIEW; RISK FACTOR; SERODIAGNOSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ARTHRITIS, REACTIVE; CHLAMYDIA INFECTIONS; HLA-B27 ANTIGEN; HOST-PARASITE RELATIONS; HUMANS;

EID: 3042532002     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000126150.04251.f9     Document Type: Review

References (74)

1. Zeidler HK, Schumacher HR: Chlamydia-induced arthritis. In The Spondyloarthritides. Edited by Calin A, Taurog JD. Oxford, New York, Tokyo: Oxford University Press; 1998:69-96.
2. Wollenhaupt J, Zeidler H: Undifferentiated arthritis and reactive arthritis. Curr Opin Rheumatol 1998, 10:306-313.
3. Inman RD, Whittum-Hudson JA, Schumacher HR, et al.: Chlamydia and associated arthritis. Curr Opin Rheumatol 2000, 12:254-262.
4. Wollenhaupt J, Kolbus F, Weissbrodt H, et al.: Manifestations of chlamydia induced arthritis in patients with silent versus symptomatic urogenital chlamydial infection. Clin Exp Rheumatol 1995, 13:453-458.
5. Schumacher HR, Gérard HC, Arassi TK, et al.: Lower prevalence of Chlamydia pneumoniae DNA compared with Chlamydia trachomatis DNA in synovial tissue of arthritis patients. Arthritis Rheum 1999, 42:1889-1893.
6. Söderlin MK, Börjesson O, Kautiainen H, et al.: Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002, 61:911-915.
7. Söderlin MK, Kautiainen H, Puolakkainen M, et al.: Infections preceding early arthritis in Southern Sweden: a prospective population-based study. J Rheumatol 2003, 30:459-464. This population-based study of patients with early arthritis of less than 3 months' duration describes the frequency of previous infections identified by history, serology, and C. trachomatis DNA in first-void urine.
8. Savolainen E, Kaipiainen-Seppänen O, Kröger L, et al.: Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003, 30:2460-2468. This epidemiologic study reports the total incidence and distribution of inflammatory joint diseases in a defined population in Finland with reference to reactive arthritides and C. trachomatis infections
9. Kvien TK, Glennas A, Melby K, et al.: Reactive arthritis: incidence, triggering agents and clinical presentation. J Rheumatol 1994, 21:115-122.
10. Isomäki H, Raunio J, von Essen R, et al.: Incidence of inflammatory rheumatic diseases in Finland. Scand J Rheumatol 1978, 7:188-192.
11. Kobayashi S, Tamura N, Ichikawa G, et al.: Infection related arthritis induced by tonsillar Chlamydia trachomatis and Streptococcal infection [letter]. Clin Exp Rheumatol 2002; 5: 732.
12. Haller-Schober EM, El-Shabrawi Y: Chlamydial conjunctivitis (in adults), uveitis, and reactive arthritis, including SARA: sexually acquired reactive arthritis. Best Pract Res Clin Obstet Gynaecol 2002, 16:815-828.
13. Hedin G, Eriksson I, Kumlin U, et al.: A lack of serologic evidence of transmission of Chlamydia pneumoniae by transfusion of buffy coat-depleted RBCs. Transfusion 2003, 43:646-650.
14. Yen JH, Tsai WC, Lin CH, et al.: Cytochrome P450 1A1 and manganese superoxide dismutase genes polymorphisms in reactive arthritis. Immunol Lett 2003, 90:151-154.
15. Hollblad-Fadiman K, Goldman SM: American college of preventive medicine practice policy statement: screening for Chlamydia trachomatis. Am J Prev Med 2003, 24:287-292. A comprehensive review of screening recommendations.
16. Bas S, Genevay S, Schenkel MC, et al.: Importance of species-specific antigens in the serodiagnosis of Chlamydia trachomatis reactive arthritis. Rheumatology 2002, 41:1017-1020.
17. Kuipers JG, Andresen J, Köhler L, et al.: Evaluation of Amplicor® Chlamydia PCR and LCX® Chlamydia LCR to detect Chlamydia trachomatis in synovial fluid. Clin Exp RheumatoFl 2002, 20:185-192.
18. Bas S, Ninet B, Delaspre O, et al.: Evaluation of commercially available tests for Chlamydia nucleic acid detection in synovial fluid of patients. Br J Rheumatol 1997, 36:198-202.
19. Nikkari S, Puolakkainen M, Yli-Kerttula U, et al.: Ligase chain reaction in detection of Chlamydia DNA in synovial fluid cells. Br J Rheumatol 1997, 36:763-765.
20. Schnarr S, Putschky N, Jendro MC, et al.: Chlamydia- and Borrelia-DNA in synovial fluid of patients with undifferentiated oligoarthritis: results of a prospective study. Arthritis Rheum 2001, 44:2679-2685.
21. Freise J, Gérard HC, Bunke T, et al.: Optimized sample DNA preparation for detection of Chlamydia trachomatis in synovial tissue by PCR and LCR. Ann Rheum Dis 2001, 60:140-145.
22. Kuipers JG, Nietfeld L, Dreses-Werringloer U, et al.: Optimized sample preparation of synovial fluid for detection of Chlamydia trachomatis DNA by polymerase chain reaction. Ann Rheum Dis 1999, 59:103-108.
23. Gérard HC, Branigan PJ, Schumacher HR, et al.: Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol 1998, 25:734-742.
24. An Q, Olive DM: Molecular cloning and nucleic acid sequencing of Chlamydia trachomatis 16S rRNA genes from patient samples lacking the cryptic plasmid. Mol Cell Probes 1994, 8:429-435.
25. Olmez N, Wang GF, Li Y, et al.: Chlamydial nucleic acids in synovium in osteoarthritis: what are the implications? J Rheumatol 2001, 28:1874-1880.
26. Cox CJ, Kempsell KE, Gaston JSH: Investigation of infectious agents associated with arthritis by reverse transcriptase PCR of bacterial rRNA. Arthritis Res Ther 2003, 5:R1-R8.
27. Villareal CH, Whittum-Hudson JA, Hudson AP: Commentary: persistent Chlamydiae and chronic arthritis. Arthritis Res 2002, 4:5-9. An informative review of the role of persistent chlamydial infection in acute and chronic arthritis, intended to extend the discussion of its pathogenesis and stimulate ideas for the improvement of treatment.
28. Kuipers JG, Zeidler H, Köhler L: How does Chlamydia cause arthritis? Rheum Dis Clin North Am 2003, 29:613-629. Comprehensive review of the present knowledge of how Chlamydia causes arthritis, including chlamydial biology, the mechanisms of persistence, and the role of the immune system and HLA-B27.
29. Morrison RP: New insights into a persistent problem - chlamydial infections. J Clin Invest 2003, 111:1647-1649. This paper comments that the tissue tropism of ocular and genital C. trachomatis strains is shown to be linked to the tryptophan synthase genotype, suggesting new insights into the persistence of chlamydial infections.
30. Caldwell HD, Wood H, Crane D, et al.: Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 2003, 111:1757-1769. The study describes that ocular trachoma clinical isolates have inactivating mutations in the C. trachomatis tryptophan synthase, whereas all genital isolates encode a functional enzyme. The functional enzyme activity is directly correlated to IFN-γ resistance through an indole rescue mechanism.
31. Gérard HC, Freise J, Wang Z, et al.: Chlamydia trachomatis genes whose products are related to energy metabolism are expressed differentially in active vs. persistent infection. Microb Infect 2002, 4:13-22.
32. Nicholson TL, Olinger L, Chong K, et al.: Global stage-specific gene regulation during the developmental cycle of chlamydia trachomatis. J Bacteriology 2003, 185:3179-3189. A comprehensive study, which describes three global stage-specific networks of gene regulation during the development cycle of C. trachomatis associated with the hallmark morphologic events.
33. Beland RJ, Nelson DE, Virok D, et al.: Transcriptome analysis of chlamydial growth during IFN-γ-mediated persistence and reactivation. Proc Natl Accad Sci USA 2003, 23:15971-15976. First transcriptome analysis of chlamydial persistence, indicating that persistence is an alternate life cycle of Chlamydia to escape the immune system.
34. Jendro MC, Deutsch T, Körber B, et al.: Infection of human monocyte-derived macrophages with Chlamydia trachomatis induces T cell apoptosis: a potential mechanism for persistent infection. Infect Immun 2000, 68:6704-6711.
35. Jendro MC, Köhler L, Kuipers JG, Zeidler H: MiniReview. Microbe-induced T cell apoptosis: subversion of the host defense system? FEMS Microbiol Lett 2002, 207:121-126. This review summarizes the evidence that microbes, including C. trachomatis, induce T cell apoptosis, which may result in the subversion of the host immune system.
36. Jendro MC, Fingerle F, Deutsch T, et al.: Chlamydia trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of tumor necrosis factor- in vitro. Med Microbiol Immunol 2004, 193:45-52. This in vitro study shows that C. trachomatis-infected macrophages induce apoptosis of activated T cells by secretion of TNF-α. Humoral apoptosis can be blocked by anti-TNF- α antibodies, whereas T cell apoptosis induced by cell-cell contact could not be blocked by TNF-α antibodies.
37. Karimi ST, Schloemer RH, Wilde CE III, et al.: Accumulation of chlamydial lipopolysaccharide antigen in the plasma membrane of infected cells. Infection Immun 1989, 57:1780-1785.
38. Nettelnbreker E, Zeidler H, Barthels H, et al.: Studies of persistent infection by Chlamydia trachomatis serovar K in TPA-differentiated U937 cells and the role IFN-gamma. J Med Microbiol 1998, 47:141-149.
39. Gerard HC, Whittum-Hudson JA, Schumacher R, Hudson AP: Differential expression of three Chlamydia trachomatis hsp60-encoding genes in active vs persistent infection. Microb Pathog 2004, 36:35-39. This study shows that the three different C. trachomatis HSP60-encoding genes are differentially regulated during active and persistent infection, which may have an impact on the induction or maintenance of a persistent infection.
40. Gaston JSH, Deane KHO, Jecock RM, Pearce JH: Identification of 2 Chlamydia trachomatis antigens recognized by synovial fluid T cells from patients with Chlamydia-induced reactive arthritis. J Rheumatol 1996, 23:130-136.
41. Bulut Y, Faure E, Thomas L, et al.: Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002, 168:1435-1440.
42. Gérard HC, Wang Z, Whittum-Hudson JA, et al.: Cytokine and chemokine mRNA produced in synovial tissue chronically infected with Chlamydia trachomatis and Chlamydia pneumoniae. J Rheumatol 2002, 29:1827-1835.
43. Bas S, Kvien K, Buchs N, et al.: Lower level of synovial fluid interferon- γ in HLA-B27-positive than in HLA-B27-negative patients with Chlamydia trachomatis reactive arthritis. Rheumatology 2003, 42:461-467.
44. Fan T, Lu H, Lu H, et al.: Inhibition of apoptosis in Chlamydia-infected cells: blockage of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998, 187:487-496.
45. Rödel J, Vogelsang H, Prager K, et al.: Role of interferon- stimulated gene factor 3γ and beta interferon in HLA class I enhancement in synovial fibroblasts upon infection with Chlamydia trachomatis. Infect Immun 2002, 70:6140-6146.
46. Zhong G, Liu L, Fan T, et al.: Degradation of transcription factor RFX5 during the inhibition of both constitutive and interferon gamma-inducible major histocompatibility complex class I expression in chlamydia-infected cells. J Exp Med 2000, 191:1525-1534.
47. Hess S, Rheinheimer C, Tidow F, et al.: The reprogrammed host: Chlamydia trachomatis-induced up-regutation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. Arthritis Rheum 2001, 44:2392-2401.
48. Hess S, Peters J, Bartling G, et al.: More than just innate immunity: comparative analysis of Chlamydophila pneumoniae and Chlamydia trachomatis effects on host-cell gene regulation. Cell Microbiol 2003, 5(11):785-795. A comprehensive comparative analysis of host-cell gene regulation in human epithelial cells during intracellular infection with C. trachomatis, C. pneumoniae, and Salmonella typhimurium.
49. Kuipers JG, Schrader S, Bialowons A, et al.: Chlamydia trachomatis induced gene expression during productive and persistent infection in human monocytes - results of semiquantitative realtime RT-PCR. Arthritis Rheum 2002, 46(suppl.):S570.
50. Yu D, Kuipers JG: Role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis. Rheum Dis Clin North America 2003, 29:21-36. This is the most recent update on the role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis.
51. Granfors K: Host-microbe interaction in reactive arthritis: does HLA-B27 have a direct effect? J Rheumatol 1998, 25:1659-1661.
52. Kuipers JG, Bialowons A, Dollmann P, et al.: The modulation of chlamydial replication by HLA-B27 depends on the cytoplasmic domain of HLA-B27. Clin Exp Rheumatol 2001, 19:47-52.
53. Ikawa T, Ikeda M, Yamaguchi A, et al.: Expression of arthritis-causing HLA-B27 on Hela cells promotes induction of c-fos in response to in vitro invasion by Salmonella typhimurium. J Clin Invest 1998, 101:263-272.
54. Young JL, Smith L, Matyszak MK, et al.: HLA-B27 expression does not modulate intracellular Chlamydia trachomatis infection of cell lines. Infect Immun 2001, 69:6670-6675.
55. Gaston JSH, Deane KHO, Jecock RM, et al.: Identification of 2 Chlamydia trachomatis antigens recognized by synovial fluid T cells from patients with Chlamydia-induced reactive arthritis. J Rheumatol 1996, 23:130-136.
56. Goodall JC, Yeo G, Huang M, et al.: Identification of Chlamydia trachomatis antigens recognized by human CD4+ T lymphocytes by screening an expression library. Eur J Immunol 2001, 31:1513-1522.
57. Matyszak MK, Gaston JSH: Characterization of CD8+ T cell clones specific for Chlamydia trachomatis. Clin Exp Rheum 2002, 20:584.
58. Kuon W, Holzhutter HG, Appel H, et al.: Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol 2001, 167:4738-4746.
59. Thiel A, Wu P, Lauster R, et al.: Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 2000, 43:2834-2842.
60. Scofield RH, Warren WL, Koelsch G, et al.: A hypothesis for the HLA-B27 immune dysregulation in spondyloarthropathy: contributions from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution. Proc Natl Acad Sci U S A 1993, 90:9330-9334.
61. Hermann E, Yu DT, Meyer zum Buschenfelde KH, et al.: HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 1993, 342:646-650.
62. Popov I, Cruz CS, Barber BH, et al.: Breakdown of CTL tolerance to self HLA-B*2705 induced by exposure to Chlamydia trachomatis. J Immunol 2002, 169:4033-4038.
63. Popov I, Dela Cruz CS, Barber BH, et al.: The effect of an anti-HLA-B27 immune response on CTL recognition of Chlamydia. J Immunol 2001, 167:3375-3382.
64. Ramos M, Alvarez I, Sesma L, et al.: Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002, 277:37573-37581.
65. Leirisalo-Repo M, Hannu T, Mattila L: Microbial factors in spondyloarthropathies: insights from population studies. Curr Opin Rheumatol 2003, 15:408-412.
66. Flores D, Marquez J, Garza M, et al.: Reactive arthritis: newer developments. Rheum Dis Clin North Am 2003, 29:37-59. Comprehensive review of reactive arthritis covering different issues, including current therapy.
67. Gaston JSH, Kvien TK, Bardin T, et al.: Three-month treatment of reactive arthritis with azithromycin: a EULAT double-blind, placebo-controlled study. Arthitis Rheum 2002, 46(suppl):S571.
68. Laasila K, Laasonen L, Leirisalo-Repo M: Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis 2003, 62:655-658. The follow-up after 10 years showed that prolonged antibiotic treatment did not alter the course of the disease.
69. Koehler L, Kuipers JG, Zeidler H: Managing seronegative spondylarthritides. Rheumatology 2000, 39:360-368.
70. Dougados M, Revel M, Khan MA: Spondyloarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baill Clin Rheumatol 1998, 12:717-736.
71. Braun J, van der Heijde D: Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Invest Drugs. 2003, 12:1097-1109. Comprehensive review of the efficacy and safety of TNF-α blocking agents in the therapy of ankylosing spondylitis and other spondyloarthritides.
72. Meador R, Hsia E, Kitumnuaypong T, Schumacher HR: TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 2002, 20(6 Suppl 28):S130-S134. Review of the available data of anti-TNF-α therapy in reactive arthritis and the potential risk of this treatment with respect to the biology of the causative bacteria. Pros and cons are discussed.
73. Oili KS, Niinisalo H, Korpilahde T, et al.: Treatment of reactive arthritis with infliximab. Scand J Rheumatol 2003, 32:122-124.
74. Braun J, Pham T, Sieper J, et al.: International ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824. The International ASAS group has made recommendations for the use of anti-TNF-α agents in patients with ankylosing spondylitis. An active disease characterized by a BASDAI >4 and elevated acute-phase parameters as well as therapy-refractory disease despite adequate use of at least two NSAIDs is required before use of this therapy.